|Dr. Richard D. Klausner M.D.||Founder & Exec. Chairman||80k||N/A||1952|
|Dr. Lynn Seely M.D., Ph.D.||Pres, CEO & Director||430.69k||N/A||1959|
|Mr. Charles W. Newton||Chief Financial Officer||1.72M||N/A||1971|
|Mr. Stephen J. Hill||Chief Operating Officer||1.04M||N/A||1970|
|Dr. Gary Lee Ph.D.||Chief Scientific Officer||639.91k||N/A||1977|
|Ms. Elizabeth Homans||Consultant||1.99M||N/A||1966|
|Prof. Stanley R. Riddell M.D.||Founder & Scientific Advisor||N/A||N/A||N/A|
|Dr. Crystal L. Mackall M.D.||Founder & Scientific Advisor||N/A||N/A||N/A|
|Nellie Dillery||Director of Accounting||N/A||N/A||N/A|
|Ms. Ellen Rose||Sr. VP of Communications & Investor Relations||N/A||N/A||N/A|
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc.’s ISS governance QualityScore as of 1 September 2023 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 8; Compensation: 9.